# Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

> **NCT04740021** · PHASE2 · UNKNOWN · sponsor: **Taizhou HoudeAoke Biomedical Co., Ltd.** · enrollment: 46 (estimated)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

- **DRUG:** LP002
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT04740021
- **Lead sponsor:** Taizhou HoudeAoke Biomedical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-02
- **Primary completion:** 2022-02-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2021-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04740021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04740021, "Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04740021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*